1. MacLean AB. Urinary tract infection and pregnancy. In: Cattell WR, editor. Infections of the Kidney and Urinary Tract. Oxford University press, 1996.
2. Kass EH. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann Int Med 1962; 56: 46–53.
3. McFadyen IR, Single-dose treatment of bacteriuria in pregnancy. Eur Urol 1987; 13 (Suppl. 1): 22–5.
4. Рафальский В.В., Малеев И.В., Рохликов И.М., Деревицкий А.В. Рациональная антибактериальная терапия амбулаторных инфекций мочевыводящих путей с учетом данных по резистентности основных уропатогенов в России. Трудн. пациент. 2006; 9 (4): 25–8.
5. K.G.Naber (председатель), M.C.Bishop, T.E.Bjerklund Johansen и др. Рекомендации Европейской урологической ассоциации по ведению больных с инфекциями почек, мочевыводящих путей и инфекциями мужских половых органов. Смоленск, 2008.
6. Raz R, Chazan B, Kennes Y et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34 (9): 1165–9.
7. Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29 (4): 745–58.
8. Nicolle LE. Resistant pathogens in urinary tract infections. J Am Geriatr Soc 2002; 50 (Suppl. 7): S230–5.
9. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б. Белоусова, С.Н.Козлова. Смоленск: МАКМАХ, 2007; 76–85.
10. Яковлев С.В., Деревянко И.И. Какие антибиотики действительно нужны для лечения урогенитальных инфекций? Consilium Medicum 2004; 6 (1): 40–5.
11. Debbia EA, Pesce A, Chiesa M et al. Microbiologic profile of ceftibuten, a new oral cephalosporin. Drugs Under Exp Clin Res 1992; 18 (4): 129–39.
12. Jones RN. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis 1993; 12: 37–43.
13. Nickel JC. Management of urinary tract infections: historical perspective and current strategies. Part 2. Modern management. J Urol 2005; 173: 27–32.
14. Klepser ME, Marangos MN, Patel KB et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 1995; 28: 361–84.
15. Lode H, Fassbender M, Schaberg T et al. Comparative pharmacokinetics of the new oral cephalosporins. Drugs 1994; 47 (Suppl. 3): 10–9.
16. Periti P, Mazzei T, Mini E, Novelli A. Ceftibuten, clinical pharmacology and chemotherapy. Farmaci Terapia 1992; IX (Suppl. 1).
17. Wiseman LR, Balfour JA. Ceftibuten-a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994; 47 (5): 784–808.
18. Brismar B, Edlund C, Nord CE. Effect of ceftibuten on the normal intestinal microflora. Infect 1993; 21: 373–5.
19. Jones RN. Antimicrobial activity and spectrum of ceftibuten – a review of United States and Canadian results. Diagn Microbiol Infect Dis 1991; 14 (1): 37–43.
20. Vranes J, Marijan T, Bedenic B et al. Clonal dissemination of highly virulent extended-spectrum β-лактаmase-producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region. Int J Antimicrob Age 2008; 31S; S19–24.
21. Cormican M, Morris D, Corrbet-Feeney G. Extended spectrum β-lactamase production and fluoroquinolone resistanse in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis 1998; 32: 317–9.
22. Wiseman LR, Balfour JA. Ceftibuten: a review of antibacterial activity, pharmacokinetic properties, and clinical efficacy. Drug 1994; 47 (5): 784–808.
23. Bauernfeind A. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases, Diagn Microbiol Infect Dis 1991; 14 (1): 89–92.
24. Debbia EA, Pesce A, Chiesa M et al. Microbiologic profile of ceftibuten, a new oral cephalosporin. Drugs Exp Clin Res 1992; 18 (4): 129–39.
25. Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases, Antimicrob Agents Chemother. 1990; 34 (5): 858–62.
26. Suzuki K, Nagata Y, Horiba M. Clinical studies on ceftibuten in the urinary field infection. Jpn J Antibiot1990; 43 (11): 2003–10.
27. Hashimoto H, Yamaguchi S, Yachiku S et al. Clinical Studies of ceftibuten in the field of urology. Jpn J Antibiot 1990; 43 (2): 355–61.
28. Mao-Wang Ho, Fu-Der Wang, Chang-Phone Fung, Cheng-Yi Lui. Comparative study of ceftibuten and cefixime in the treatment of complicated urinary tract infections. J Microbiol Immunol Infect 2001; 34: 185–18.
29. Рекомендации EAU 2006–2007. Под ред. Н.А.Лопаткина, О.ИАполихина, Р.С.Козлова, Т.С.Перепановой. www.antibiotoc.ru глава 2.8.3.
30. Krcmery S. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents 17 (4): 279–82.
31. Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1818–4.
32. Sbarbaro JA. Strategies to improve compliance with therapy. Am J Med 1985; 79: 34–7.